Efficacy and safety of immunosuppressive therapy combined with eltrombopag for severe aplastic anemia: a systematic review and meta-analysis

Table 2 Subgroup analysis of different study designs

Outcomes	Subgroup	Number of included studies	IST+/IST	Pooled effects			p value for interaction	Heterogeneity
Outcomes	Subgroup	Number of included studies	IST+/IST	OR	95% CI	p value	p value for interaction	I²/%	p value
ORR at 3 months	Cohort studies	8	233/384	1.86	[1.31, 2.65]	0.0006	0.297	0	0.64
ORR at 3 months	RCT	2	145/150	2.49	[1.29, 4.82]	0.007	0.297	44	0.18
ORR at 6 months	Cohort studies	12	644/776	2.08	[1.50, 2.89]	< 0.0001	0.815	30	0.15
ORR at 6 months	RCT	3	190/195	2.30	[1.07. 4.92]	0.03	0.815	54	0.11
ORR at 12 months	Cohort studies	6	197/281	1.12	[0.66, 1.89]	0.68	0.849	26	0.24
ORR at 12 months	RCT	1	49/49	1.28	[0.58, 2.83]	–	0.849	–	0.54
CRR at 3 months	Cohort studies	7	209/373	2.71	[1.62, 4.56]	0.0002	0.967	0	0.74
CRR at 3 months	RCT	2	145/150	2.76	[1.45, 5.25]	0.002	0.967	0	0.75
CRR at 6 months	Cohort studies	11	620/765	3.11	[2.20, 4.41]	< 0.00001	0.122	29	0.17
CRR at 6 months	RCT	3	190/195	1.97	[1.25, 3.09]	0.003	0.122	0	0.91
CRR at 12 months	Cohort studies	6	197/281	1.48	[0.83, 2.62]	0.18	0.620	46	0.10
CRR at 12 months	RCT	1	49/49	1.00	[0.43, 2.33]	–	0.620	–	1.00

Bold values indicate statistically significant values at p < 0.05
IST immunosuppressive therapy, EPAG eltrombopag, OR odds ratio, CI confidence interval, ORR overall response rate, CRR complete response rate, RCT randomized controlled trial

ISSN: 2046-4053